Eli Lilly and CompanyvsRapport Therapeutics

LLY and RAPP stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,391.10

Value $1.31T

-1.70%
LLY's page

RAPP

Rapport Therapeutics, Inc.

$23.53

Value $1.1B

-0.98%
RAPP's page

Eli Lilly and Company (LLY) has a market value of $1.31T and Rapport Therapeutics (RAPP) $1.1B. Over the last year, with dividends, LLY moved +37.0% and RAPP -6.3%. Dividend yield: LLY 0.46%, RAPP none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.31T

    RAPP$1.1B

    LLY is 1,167 times RAPP

  • Revenue, 12 months

    LLY$86.5B

    RAPP–

  • Net income, 12 months

    LLY$27.6B

    RAPP-$150M

  • Operating margin

    LLY–

    RAPP–

  • ROIC

    LLY35.5%

    RAPP-20.4%

    55.9 points apart

  • P/E

    LLY47.6

    RAPP–

  • Dividend yield

    LLY0.5%

    RAPP0.0%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+37.0%

RAPP-6.3%

100150200DecFebAprJunAugOct
Returns by period
PeriodLLYWith dividendsRAPPWith dividends
1 year since November 17, 2025+37.0%Price +36.2%-6.3%Price -6.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyRAPPRapport Therapeutics

Valuation

LLYRAPP
Valuation
Price$1,391.10$23.53
Market value$1.31T$1.1B
Enterprise value (EV)$1.36T$729M
P/E47.6–
P/E, 5-year median49.9–
P/B32.62.9
EV/EBIT39.0–
Free cash flow yield1.5%–

Results and growth

LLYRAPP
Results and growth
Revenue, 12 months$86.5B–
Net income, 12 months$27.6B-$150M
Free cash flow, 12 months$19.7B-$121M
Earnings per share, 12 months$30.81-$3.16
Revenue growth, year on year44.7%–
Revenue growth a year, past+21.6%over 5 years–
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYRAPP
Margins and returns on capital
Gross margin83.6%–
Operating margin––
Net margin31.9%–
ROIC35.5%-20.4%
ROE88.6%-33.0%

Balance sheet

LLYRAPP
Balance sheet
Cash$4.9B$395M
Total debt$49.5B$9.4M
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYRAPP
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%0.0%
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or RAPP

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Rapport Therapeutics?

By market value, Eli Lilly and Company ($1.31T) is about 1,167.0 times Rapport Therapeutics ($1.1B), at today's prices.

How did LLY and RAPP stock do over the last 1 years?

Since November 17, 2025, LLY's price moved +36.2% and RAPP's -6.3%. With dividends: LLY +37.0% (+37.0% a year), RAPP -6.3% (-6.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or RAPP?

The dividend yield at today's price is 0.46% for Eli Lilly and Company and none for Rapport Therapeutics. Over the last twelve months they paid $6.34 and – per share.

Which is the better investment, Eli Lilly and Company or Rapport Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.